Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosisSergio E. Baranzini, Jorge R. Oksenberg, Joanne Wang et al.|Human Molecular Genetics|2008Cited by 479
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)Alyssa A Toorop, Zoé L. E. van Kempen, Zoë YGJ van Lierop et al.|Journal of Neurology Neurosurgery & Psychiatry|2023Cited by 17
Don’t be late! Timely identification of cognitive impairment in people with multiple sclerosis: a study protocolPauline T. Waskowiak, Thijs van‘t Hullenaar, Guy Widdershoven et al.|BMC Neurology|2024Cited by 13
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trialAlyssa A Toorop, Zoé L. E. van Kempen, Mark HJ Wessels et al.|Journal of the Neurological Sciences|2024Cited by 6
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patientsAlyssa A Toorop, Charlotte E. Teunissen, Mark HJ Wessels et al.|Multiple Sclerosis Journal|2024Cited by 3